<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Standard salvage chemotherapy for refractory or relapsed malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> has not been defined </plain></SENT>
<SENT sid="1" pm="."><plain>The efficacy and feasibility of the <z:chebi fb="10" ids="39061">ACES</z:chebi> regimen, consisting of <z:chebi fb="2" ids="31355">carboplatin</z:chebi> at 100 mg/m(2) on day 1 to 4, <z:chebi fb="0" ids="4911">etoposide</z:chebi> at 80 mg/m(2) on day 1 to 4, high-dose Ara-C at 2 g/m(2) on day 5 and <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> at 500 mg/day for 5 days, for refractory or relapsed <z:hpo ids='HP_0002665'>lymphoma</z:hpo> were retrospectively reviewed in comparison with the ESHAP regimen </plain></SENT>
<SENT sid="2" pm="."><plain>The subjects were 29 patients, including 7 aggressive follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, 16 large B cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and 6 Hodgkin <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Characteristics of patients with ESHAP (19 cases) and the <z:chebi fb="10" ids="39061">ACES</z:chebi> (10 cases) group were as follows: male/female ratio, 10/9 and 3/7; median age, 49 (range, 31-72) and 54 (22-65); and initial clinical stage (I and II / III / IV), 5/8/6 and 1/1/8, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>Among the 29 patients, complete response was achieved in 68% (13/19) in ESHAP and 40% (4/10) in <z:chebi fb="10" ids="39061">ACES</z:chebi>.Progression-free survival and overall survival were 31.3% and 34.3%, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>Hematological toxicity was not significantly different between the two groups, and renal toxicity was significantly higher in ESHAP (52%) than <z:chebi fb="10" ids="39061">ACES</z:chebi> (0%) </plain></SENT>
<SENT sid="6" pm="."><plain>We concluded that the <z:chebi fb="10" ids="39061">ACES</z:chebi> regimen had a possibility of effective consolidation therapy for the elderly aiming to undergo autologous stem cell transplantation </plain></SENT>
</text></document>